CClinicalTrials.gg
CompletedNCT03152253Updated Apr 25, 2019

Individually Tailored and Integrated Social Support Network for Tobacco Cessation

An interventional study of Text My Quit (TMQ) and Peer Support in Smoking Cessation, sponsored by The Miriam Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-25.

Sponsored by The Miriam Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will continue development of a quit smoking program delivered through text messaging. Upon completion of programming we will enroll 280 participants and randomize them to a control condition or the intervention condition. Assessments will occur at enrollment, and both 3 and 6 month follow ups.

Read the detailed description

This study builds on pilot work in which Live Inspired LLC and research partners developed T2Q (formerly "Text-2-Quit") a smoking cessation intervention delivered through text messaging. T2Q is a unique program with a number of features that provide superior support and service compared to existing text message quit smoking products. T2Q is 100% accessible through text messaging provides medication support for quitting smoking, an integrated social support network and live counseling. This phase II project will add functionality to accommodate use of multiple forms of quit smoking medications, and then conduct a rigorous test of the efficacy of T2Q among 280 adult smokers and examine smoking outcomes compared to controls at 3 and 6 months follow up. The study will also examine changes in smoking-related attitudes and behaviors among T2Q users to identify strengths and any potential weaknesses that may affect T2Q's impact on smoking outcomes. Analyses will examine the quality of social interactions within the T2Q integrated social support network and their role in promoting smoking abstinence. We will also conduct interviews with study participants in the T2Q arm to enable understanding of the user's experience with T2Q. Results of this trial will demonstrate the efficacy of T2Q - providing important credibility needed for successful commercialization. This research will also provide important data for possible enhancements to improve consumer appeal prior to commercialization.

This proposal finalizes development and testing of a unique, highly scalable intervention that can reach a U.S. market comprised of over 34 million adult smokers who use text messaging, and provide them with effective, evidence-based treatment. Text messaging enjoys near-market saturation and is a widely preferred method of communication with deep penetration across diverse groups. Wide availability of an attractive and effective smoking cessation program such as T2Q, may exert a powerful, sustained impact on public health

02

Conditions studied

  • Smoking Cessation

Keywords

  • Tobacco, Smoking, Text Message
03

In context

Lead sponsor

The Miriam Hospital is the lead sponsor of 178 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age >18
  • current daily cigarette smoker
  • use of text messaging at least once per week
  • interested in quitting smoking within the next 30 days
  • has access to a physician or healthcare provider
  • no current drug/alcohol abuse.

Exclusion criteria

Exclusion Criteria:

  • Non-English Speaking
  • Currently using quit-smoking medications or therapies
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Text Message for Smoking Cessation

    smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room

    Behavioral: Text My Quit (TMQ) · Behavioral: Peer Support

  • Placebo comparator
    Non-Interventional Text Messages

    General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.

    Behavioral: Peer Support · Other: Motivational Messages

Interventions

  • BehavioralText My Quit (TMQ)

    Text messages designed to aid smoking cessation

  • BehavioralPeer Support

    A group chat room for peer support

  • OtherMotivational Messages

    Generic motivational messages not related to smoking cessation

06

What researchers measure

Primary outcomes

  1. Smoking Abstinence

    Self-report of no smoking for the past 7 days

    Time frame: 6 month follow up

Secondary outcomes

  1. Social support network use

    number of messages sent to the chat room

    Time frame: 12 weeks

07

Study locations

1 site
  • The Miriam Hospital- CORO building
    Providence, Rhode Island 02903, United States
08

References and documents

Publications

  • Bock BC, Rosen RK, Barnett NP, Thind H, Walaska K, Foster R, Deutsch C, Traficante R. Translating Behavioral Interventions Onto mHealth Platforms: Developing Text Message Interventions for Smoking and Alcohol. JMIR Mhealth Uhealth. 2015 Feb 24;3(1):e22. doi: 10.2196/mhealth.3779. PubMed 25714907 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03152253
Lead sponsor
The Miriam Hospital
Collaborators
Live Inspired, LLC
Responsible party
Sponsor
First posted
May 12, 2017
Start date
May 30, 2017
Primary completion
Nov 30, 2018
Completion
Nov 30, 2018
Last update
Apr 25, 2019

Study contacts

Christopher Deutsch, BS
principal investigator · Live Inspired, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion